Innate Immune Signaling Pathways in Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
The innate immune system plays a dual role in Alzheimer's disease (AD): initially mounting protective responses to clear pathological protein aggregates, but ultimately driving chronic neuroinflammation that accelerates neurodegeneration. Pattern recognition receptors (PRRs) — including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and cytosolic DNA sensors — detect amyloid-beta and other danger-associated molecular patterns (DAMPs), activating downstream signaling cascades involving NF-kappaB, the NLRP3 inflammasome, and the cGAS-STING pathway["heneka2015"].
Genome-wide association studies (GWAS) have identified numerous AD risk loci in innate immune genes — including TREM2, CD33, INPP5D, PLCG2, ABI3, and ABCA7 — establishing neuroinflammation as a core pathogenic mechanism rather than a secondary consequence of neurodegeneration["el2017"][sims2017].
Toll-Like Receptor Signaling
TLR2 and TLR4
TLR4 is the most extensively studied innate immune receptor in AD. It recognizes fibrillar and oligomeric amyloid-beta as a DAMP, initiating MyD88-dependent signaling that activates NF-κB and MAPK pathways[li2023].
Upon amyloid-beta binding, TLR4 forms a complex with MD-2 and CD14, triggering:
- MyD88-dependent pathway: Rapid activation of NF-κB and AP-1, leading to pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1β)
- TRIF-dependent pathway: Activation of IRF3 and type I interferon production
The role of TLR signaling in AD is profoundly context-dependent: acute TLR activation promotes microglial phagocytosis and amyloid clearance, while chronic activation drives sustained cytokine production, synaptic damage, and neuronal death.
TLR9 and Mitochondrial DNA Sensing
TLR9, an endosomal receptor that recognizes unmethylated CpG DNA, is activated by mitochondrial DNA (mtDNA) released from damaged neurons. Mitochondrial dysfunction in AD leads to mtDNA release into the cytoplasm and extracellular space, where it acts as a potent DAMP.
NLRP3 Inflammasome
The NLRP3 inflammasome is a key driver of chronic neuroinflammation in AD[heneka2015]. NLRP3 inflammasome activation requires two sequential signals:
Priming signal (Signal 1): TLR or NF-κB activation upregulates NLRP3 and pro-IL-1β expression
Activation signal (Signal 2): Amyloid-beta fibrils trigger activation through lysosomal disruption, potassium efflux, mitochondrial ROS generation, and calcium influx[li2023]The NLRP3 inflammasome contributes to tau pathology progression through IL-1β-mediated activation of kinases that phosphorylate tau, including GSK-3β and CDK5[ising2019].
ASC Specks and Cross-Seeding
A critical pathogenic mechanism is the discovery that ASC specks released from pyroptotic microglia cross-seed amyloid-beta in the brain[venegas2017]. ASC specks:
- Are remarkably stable and persist in the extracellular space
- Can be phagocytosed by neighboring microglia
- Act as nuclei for amyloid-beta aggregation
- Spread pathology between brain regions
cGAS-STING Pathway
The cGAS-STING pathway is a cytosolic DNA-sensing mechanism activated by cGAS, which detects double-stranded DNA in the cytoplasm. In AD, mitochondrial and nuclear DNA released from damaged neurons activates cGAS-STING, driving type I interferon (IFN-I) production[xie2022].
STING and Tau Pathology
STING activation contributes to tau pathology through interferon-mediated upregulation of kinases that phosphorylate tau, including GSK-3β and CDK5. In tauopathy mouse models, genetic deletion of STING reduces tau phosphorylation, neuroinflammation, and neurodegeneration.
STING and Microglial Dysfunction
STING activation in microglia promotes a neurotoxic inflammatory phenotype while impairing phagocytic function. The resulting type I interferon response upregulates complement components, chemokines (CXCL10, CCL2), and antigen presentation molecules (MHC-II), amplifying the broader neuroinflammatory cascade.
TREM2 Signaling
Structure and Function
TREM2 (triggering receptor expressed on myeloid cells 2) is expressed primarily on microglia and serves as a critical regulator of microglial survival, proliferation, and function. TREM2 binds amyloid-beta and lipid ligands, triggering signaling through the adaptor protein DAP12 (TYROBP)[el2017].
TREM2 Variants and AD Risk
Rare coding variants in TREM2 are associated with dramatically increased AD risk (heterozygous variants increase risk 2-4×)[el2017]. The R47H variant specifically impairs TREM2's ability to bind amyloid-beta and lipid ligands, reducing microglial activation around plaques.
Microglial States
Single-cell RNA sequencing has revealed multiple microglial states in AD[kerenshaul2017]:
- Homeostatic microglia: Present in normal brain
- Disease-associated microglia (DAM): Upregulated in AD, characterized by increased TREM2 expression and lipid metabolism genes
- IFN-responsive microglia: Upregulated type I interferon response genes
Complement System
The complement system provides innate immune defense through opsonization, inflammation, and membrane attack complex (MAC) formation. In AD, complement components C1q, C3, and C4 are significantly upregulated, particularly around amyloid plaques and degenerating synapses[hong2016].
C1q binds to synapses in an age- and amyloid-dependent manner, initiating the classical complement cascade that culminates in C3b/iC3b deposition on synaptic membranes. Complement receptor 3 (CR3/CD11b) on microglia then mediates phagocytic removal of tagged synapses[hong2016].
Key findings:
- C1q is increased and associated with synapses before overt plaque deposition in mouse models
- Inhibition of C1q, C3, or CR3 reduces the number of phagocytic microglia at synapses
- C1q initiates the complement cascade, leading to synaptic loss
Therapeutic Implications
Precision Immunomodulation
The dual protective/destructive nature of innate immunity in AD necessitates precision approaches rather than broad immunosuppression. Multiple clinical trials of NSAIDs failed in AD, likely because these agents suppress both harmful and protective immune functions.
Current therapeutic strategies:
| Target | Approach | Stage | Status |
|--------|----------|-------|--------|
| TREM2 | Agonist antibodies (AL002, JZH6) | Phase II | Active trials |
| NLRP3 | Small molecule inhibitors | Preclinical | Development |
| C1q | Anti-C1q antibody (ANX005) | Phase II | Recruiting |
| STING | STING antagonists (H-151) | Preclinical | Proof of concept |
Biomarker-Guided Therapeutic Timing
Inflammatory biomarkers can identify patients with prominent neuroinflammation and guide therapeutic timing:
- sTREM2: Soluble TREM2, peaks during early symptomatic stages
- YKL-40: CSF marker of astrocytic inflammation
- IL-6, TNF-alpha: Pro-inflammatory cytokines in CSF
- Complement fragments (C4a, C3a): Reflect complement cascade activation
Integrated Pathway Model
Cross-References
- TREM2 Gene — Key microglial receptor and AD risk gene
- Microglia — Primary innate immune cells of the brain
- NLRP3 Inflammasome — Inflammasome pathway in AD
- cGAS-STING in Neurodegeneration
- NF-κB Signaling in Neuroinflammation
- Complement System
See Also
- Alzheimer's Disease
- Neuroinflammation
- Amyloid Cascade Hypothesis
- Microglial Phagocytosis
- All Mechanisms
References
Heneka MT et al., Nature 2015 — NLRP3 is activated in AD
Ising C et al., Nat Neurosci 2019 — NLRP3 drives tau pathology
Hong S et al., Acta Neuropathol 2016 — Complement mediates synapse loss
Keren-Shaul H et al., Cell 2017 — DAM microglia in AD
Venegas C et al., Nature 2017 — ASC specks cross-seed Aβ
Xie X et al., Nat Neurosci 2022 — cGAS-STING in AD
Li Y et al., J Neuroinflammation 2023 — TLR4-NLRP3 signaling
Sims R et al., Nat Neurosci 2017 — Rare variants in PLCG2, ABI3, TREM2Pathway Diagram
The following diagram shows the key molecular relationships involving Innate Immune Signaling Pathways in Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)